Comparison of the Additive Intraocular Pressure???Lowering Effect of Latanoprost and Dorzolamide When Added to Timolol in Patients With Open-angle Glaucoma or Ocular Hypertension: A Randomized, Open-label, Multicenter Study in Greece

Petounis, Andreas; Mylopoulos, Nikolaos; Kandarakis, Artemios; Andreanos, D; Dimitrakoulias, N.

doi:10.1097/00061198-200108000-00012

Cited by 31 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In timolol-treated subjects, adjunctive latanoprost lowered IOP signif icantly more than adjunctive dorzolamide (−7.06 mmHg; 32% vs −4.44 mmHg; 20% for adjunctive latanoprost and dorzolamide respectively) after 3-months in one study 175 and more than adjunctive pilocarpine 2%, 3 times daily in another. 130,176,177 Addition of latanoprost to pilocarpine therapy does not appear to diminish uveoscleral outflow 178,179 but is instead additive, 178,[180][181][182][183] contrary to thoughts that ciliary muscle contraction with cholinergics hinders uveoscleral outflow.…”

Section: Adjunctive Therapymentioning

confidence: 88%

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Lee

McCluskey

2010

OPTH

View full text Add to dashboard Cite

Prostaglandin analogs (PGA) are powerful topical ocular hypotensive agents available for the treatment of elevated intraocular pressure (IOP). Latanoprost 0.005% and travoprost 0.004% are prodrugs and analogs of prostaglandin F2α. Bimatoprost 0.03% is regarded as a prostamide, and debate continues as to whether it is a prodrug. The free acids of all 3 PGAs reduce IOP by enhancing uveoscleral and trabecular outflow via direct effects on ciliary muscle relaxation and remodeling of extracellular matrix. The vast majority of clinical trials demonstrate IOP-lowering superiority of latanoprost, bimatoprost and travoprost compared with timolol 0.5%, brimonidine 0.2%, or dorzolamide 2% monotherapy. Bimatoprost appears to be more efficacious in IOPlowering compared with latanoprost, with weighted mean difference in IOP reduction documented in one meta-analysis of 2.59% to 5.60% from 1-to 6-months study duration. PGAs reduce IOP further when used as adjunctive therapy. Fixed combinations of latanoprost, bimatoprost or travoprost formulated with timolol 0.5% and administered once daily are superior to monotherapy of its constituent parts. PGA have near absence of systemic side effects, although do have other commonly encountered ocular adverse effects. The adverse effects of PGA, and also those found more frequently with bimatoprost use include ocular hyperemia, eyelash growth, and peri-ocular pigmentary changes. Iris pigmentary change is unique to PGA treatment. Once daily administration and near absence of systemic side effects enhances tolerance and compliance. PGAs are often prescribed as first-line treatment for ocular hypertension and open-angle glaucoma.

show abstract

Section: Adjunctive Therapymentioning

confidence: 88%

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Lee

McCluskey

2010

OPTH

View full text Add to dashboard Cite

show abstract

“…Therefore, control of IOP was achieved during the two months of the clinical protocol, regardless of the period and sequence of study (F (4,192) =1.442, p=0.222). The efficacy in controlling IOP showed no statistical differences between the two groups (F (1,48) =0.1675, p=0.898) (Figure 2).…”

Section: Efficacymentioning

confidence: 97%

“…Prostaglandin analogues (PGA) are the most effective either alone or in combination with autacoids. The esterification of carboxylic acid in a PGF2α reduces the amount of medication required to decrease intraocular pressure (IOP) and so acts to reduce the side effects associated with the PGA [4,5].…”

Section: Introductionmentioning

confidence: 99%

A phase III, randomized, clinical, crossover study to evaluate the non-inferiority of an ophthalmic solution of preservative-free latanoprost at 0.005% in patients with primary open-angle glaucoma

Sánchez-Castellanos¹,

Paczka²,

Gomez-Aguayo³

et al. 2018

New Front Ophthalmol

View full text Add to dashboard Cite

“…Note that a total of 18 studies (2943 patients) were included in this MTC, 20,23,28,37,40,51,55,60,73,78,89,[91][92][93][94]98,107,109 as these were the only studies included in the SR extraction that reported sufficient data on mean and standard deviation in IOP.…”

Section: Trigger For Treatment Switch 2: Failure To Meet Iop Targetsmentioning

confidence: 99%

Long-term Medical Management of Primary Open-Angle Glaucoma and Ocular Hypertension in the UK

Orme

Collins

Loftus

2012

Journal of Glaucoma

View full text Add to dashboard Cite

Drug acquisition costs are not a key driver of the total cost of glaucoma management and the cost of medical therapy is offset by avoiding the cost of managing low vision. Economic models of glaucoma should include the long-term consequences of treatment as these will affect cost-effectiveness. This analysis supports the hypothesis that the economic and clinical benefits can be optimized by minimizing therapy switches.

show abstract

Comparison of the Additive Intraocular Pressure???Lowering Effect of Latanoprost and Dorzolamide When Added to Timolol in Patients With Open-angle Glaucoma or Ocular Hypertension: A Randomized, Open-label, Multicenter Study in Greece

Abstract: This study clearly showed that the additive diurnal intraocular pressure-lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol.

Cited by 31 publications

References 34 publications

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

A phase III, randomized, clinical, crossover study to evaluate the non-inferiority of an ophthalmic solution of preservative-free latanoprost at 0.005% in patients with primary open-angle glaucoma

Long-term Medical Management of Primary Open-Angle Glaucoma and Ocular Hypertension in the UK

Contact Info

Product

Resources

About